Cellectis
- Country
- Ownership
- -
- Employees
- 221
- Market Cap
- -
- Introduction
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
Clinical Trials
6
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
- Conditions
- B-cell Non-Hodgkin Lymphoma (B-NHL)
- Interventions
- First Posted Date
- 2022-11-07
- Last Posted Date
- 2025-08-24
- Lead Sponsor
- Cellectis S.A.
- Target Recruit Count
- 80
- Registration Number
- NCT05607420
- Locations
- 🇺🇸
The University of Chicago Medical Center (UCMC), Chicago, Illinois, United States
🇺🇸Harvard Medical School - Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Rutgers Cancer Institute of New Jersey (CINJ) - New Brunswick, New Brunswick, New Jersey, United States
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
- Conditions
- B-cell Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2019-11-04
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- Cellectis S.A.
- Target Recruit Count
- 52
- Registration Number
- NCT04150497
- Locations
- 🇺🇸
University of California, Los Angeles (UCLA) - Medical Center, Los Angeles, California, United States
🇺🇸University of Colorado - Aurora Cancer Center, Aurora, Colorado, United States
🇺🇸Sarah Cannon - Colorado Blood Cancer Institute, Denver, Colorado, United States
Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)
- Conditions
- Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2019-10-29
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Cellectis S.A.
- Target Recruit Count
- 11
- Registration Number
- NCT04142619
- Locations
- 🇺🇸
UCSF Medical Center- Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸Sarah Cannon Research Institute - Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸Winship Cancer Institute Emory University, Atlanta, Georgia, United States
Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukaemia
- First Posted Date
- 2019-09-26
- Last Posted Date
- 2020-07-14
- Lead Sponsor
- Cellectis S.A.
- Registration Number
- NCT04106076
Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN
- Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- First Posted Date
- 2017-06-29
- Last Posted Date
- 2019-07-31
- Lead Sponsor
- Cellectis S.A.
- Target Recruit Count
- 1
- Registration Number
- NCT03203369
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
- Prev
- 1
- 2
- Next